Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 3Completed 2Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 1

Interventions

pembrolizumab 85Specimen Handling 79Carboplatin 73Magnetic Resonance Spectroscopy 71Biopsy 58Nivolumab 55Cisplatin 54Paclitaxel 46Cyclophosphamide 44durvalumab 37Radiotherapy 36Radiation 35olaparib 34Rituximab 34Etoposide 33Dexamethasone 33Ipilimumab 30Gemcitabine 30Lenalidomide 28Taxes 27Doxorubicin 27Docetaxel 27Pemetrexed 26Bevacizumab 24Prednisone 23Cytarabine 23X-Rays 22Trastuzumab 21cabozantinib 20Disulfides 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Has results × anetumab ravtansine × Clear all
NCT03126630 2026-04-01

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
49 enrolled 20 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡